AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03242876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control will be 109 g white bread to be consumed together with 200 mL water
Study NCT03242876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
Study NCT03901833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Support
Description: Telemedicine intervention
Study NCT03901833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT03778931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 400 mg/day once daily oral dosing
Study NCT03778931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~* Anastrozole 1 mg/day on a continuous dosing schedule~* Letrozole: 2.5 mg/day on a continuous dosing schedule~* Exemestane: 25 mg/day on a continuous dosing schedule
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300mg taken twice daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg administered orally once daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: * Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg orally twice daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 500mg orally once daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg orally twice daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25mg infused over a 30-60 minute period once a week
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg orally, once daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab
Description: Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus Cobimetinib
Description: Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150mg taken orally, once daily
Study NCT03297606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg taken orally, twice daily
Study NCT03680664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
Study NCT02836574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC).
Study NCT03680664 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
Study NCT03680664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
Study NCT02836574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC).
Study NCT03680664 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MBSR
Description: After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
Study NCT02836574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Biopsy
Description: a procedure in which a small sample of kidney tissue is removed
Study NCT02836574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Biopsy
Description: a procedure in which a small sample of kidney tissue is removed
Study NCT04698538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
Study NCT03823144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
Study NCT03823144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV as part of IVM procedure
Study NCT03068325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-EAT
Study NCT03112941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
Study NCT03112941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen group
Description: Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
Study NCT03652805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPL344
Description: The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.
Study NCT01555190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol 1500 gr
Study NCT01555190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol 2000 gr + folic acid 200 mcg
Study NCT00985985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg or 4 mg nicotine lozenge
Study NCT03745690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Surgery
Description: Undergo near-infrared image guided surgical resection
Study NCT00985985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lozenge
Study NCT03113929 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: Research MRI
Study NCT03745690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Drug
Description: Given IV
Study NCT00319592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE vaccine
Description: 0.5 mL, subcutaneously
Study NCT00319592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX® vaccine
Description: 1.0 mL, subcutaneously
Study NCT03615144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan 70 mg/m2/day x 2
Study NCT03615144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Thiotepa 7.5 mg/kg/day x 2
Study NCT03615144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: Clofarabine 20-30 mg/m2/day x 5
Study NCT03615144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day x 5
Study NCT03615144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Description: antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
Study NCT03615144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS reagents
Description: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
Study NCT04448457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet
Description: 15 mcg with lockout interval of 20 min
Study NCT04448457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral tablet and oxycodone extended-release oral tablet
Description: Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
Study NCT01895881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT01895881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01707108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant (MIS Technologies)
Description: MIS Technologies Ltd. C1 Dental implants
Study NCT01481662 — intervention group
Intervention type: DEVICE
Intervention: Diffusion tensor magnetic resonance imaging of the brain
Description: Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
Study NCT04080557 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
Study NCT04024111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KONTAKT(c)
Description: KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes facilitated by two health professionals with experience of running groups for autistic children
Study NCT04024111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art group
Description: Art program, a manualized Art group delivered in a social format, has been designed for children on the Autism Spectrum delivered by health professionals with experience of running social groups for Autistic children. The Art program's participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes.
Study NCT02682823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.
Study NCT00212381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: di indolylmethane (DIM)
Description: This is the agent being studies. Similar agents have been reported to have potential activity.
Study NCT00212381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red rice bran
Description: this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules
Study NCT02682823 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.
Study NCT02682823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Study NCT03520595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica 200 drug 3 pills,3 times daily for 3 days
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study NCT02682823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Study NCT01259349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one percent ultrasound power in CMICS
Description: Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
Study NCT01259349 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 40 percent ultrasound power in CMICS
Description: Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
Study NCT00613691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
Study NCT04053712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: GlucaGen(R), Novo Nordisk, DK
Study NCT04053712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study NCT04053712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Closed-loop system
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study NCT01137110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief LEV
Description: Levetiracetam 1000mg BID x 3 days for prophylaxis
Study NCT01137110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extended LEV
Description: Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
Study NCT05927740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
Study NCT03108768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid (Successor of Phonak Virto V)
Description: The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
Study NCT03108768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid (Phonak Virto V)
Description: Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
Study NCT01769508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, 225 mg/m2 IVCI, during XRT.
Study NCT01769508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
Study NCT01769508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
Study NCT01769508 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
Study NCT03400709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
Study NCT03400709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment
Study NCT04288687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib Pill
Description: Niraparib 200 mg by mouth daily (2 x 100 mg pills)
Study NCT01281670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vibration
Description: 8 week vibration
Study NCT02261948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Study NCT02261948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Study NCT02990936 — intervention group
Intervention type: OTHER
Intervention: Tumor delineation
Description: Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
Study NCT03470155 — intervention group
Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: operative reconstruction
Study NCT04101682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
Study NCT04079517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: A registered SERM drug, Tamoxifen.
Study NCT04079517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: A registered SERM drug, Tamoxifen.
Study NCT03749967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Study NCT04015089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF)
Description: Infant formula with partially hydrolyzed protein
Study NCT04015089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula (SF)
Description: Infant formula with intact protein
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion
Study NCT04379596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally